PureTech Health

From Wikipedia, the free encyclopedia
PureTech Health
TypePublic
LSE: PRTC
IndustryHealthcare
Founded2005
HeadquartersBoston, United States
Key people
Christopher Viehbacher (Chairman)
Daphne Zohar (CEO)
ProductsMedicines
RevenueIncrease $11.8 million (2020)[1]
Increase $(119.5) million (2020)[1]
Decrease $4.6 million (2020)[1]
Websitepuretechhealth.com

PureTech Health is a biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

History[]

The company was founded by Daphne Zohar, an American entrepreneur, in 2005.[2] It was the subject of an initial public offering on the London Stock Exchange in June 2015.[3]

Operations[]

Companies which PureTech Health founded include Karuna Pharmaceuticals,[4] Gelesis, which has received FDA approval as a treatment for weight management,[5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders,[6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases,[7] and Follica which is developing new treatments for androgentic alopecia among others.[8] PureTech also has a pipeline of its own immunology, lymphatic and oncology based therapeutics.[9]

References[]

  1. ^ Jump up to: a b c "Annual Report 2020". PureTech Health. Retrieved 16 April 2021.
  2. ^ "PureTech's long view on biopharma". Boston Globe. 26 August 2015. Retrieved 16 August 2019.
  3. ^ "PureTech banks $171M in a London IPO to fund its biotech bets". Fierce Biotech. 19 June 2015. Retrieved 16 August 2019.
  4. ^ "PureTech Health surges as Karuna investment rockets 442%". Proactive Investors. 19 November 2019. Retrieved 14 December 2019.
  5. ^ "Gelesis raises $12 million for pill that staves off hunger". BetaBoston.com. May 16, 2014.
  6. ^ "Akili Interactive adds $13 million to Series C funding pool". The Pharma Letter. 9 August 2018. Retrieved 14 December 2019.
  7. ^ "PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant". Sharecast. 5 December 2019. Retrieved 14 December 2019.
  8. ^ "Positive Results From PureTech Affiliate Male Pattern Hair Loss Study". Morning Star. 13 June 2019. Retrieved 14 December 2019.
  9. ^ "PureTech Licenses Glyph Lymphatic Technology". FT. 29 August 2017. Retrieved 14 December 2019.

External links[]

Retrieved from ""